摘要
Background. This study aimed to develop a prediction model to distinguish renal cell carcinoma (RCC) subtypes. Methods. The radiomic features (RFs) from 5 different computed tomography (CT) phases were used in the prediction models: noncontrast phase (NCP), corticomedullary phase (CMP), nephrographic phase (NP), excretory phase (EP), and all-phase (ALL-P). Results. For the ALL-P model, all of the RFs obtained from the 4 single-phase images were combined to 420 RFs. The ALL-P model performed the best of all models, with an accuracy of 0.80; the sensitivity and specificity for clear cell RCC (ccRCC) were 0.85 and 0.83; those for papillary RCC (pRCC) were 0.60 and 0.91; those for chromophobe RCC (cRCC) were 0.66 and 0.91, respectively. Binary classification experiments showed for distinguishing ccRCC vs. not-ccRCC that the area under the receiver operating characteristic curve (AUC) of the ALL-P and CMP models was 0.89, but the overall sensitivity/specificity/accuracy of the ALL-P model was better. For cRCC vs. non-cRCC, the ALL-P model had the best performance. Conclusions. A reliable prediction model for RCC subtypes was constructed. The performance of the ALL-P prediction model was the best as compared to individual single-phase models and the traditional prediction model.
学科与关键词
- CT-based multi-phase Radiomic models for differentiating clear cell renal cell carcinomaChen, Menglin; Yin, Fu; Yu, Yuanmeng; Zhang, Haijie*; Wen, Ge*CANCER IMAGING, 2021, 21(1): 42.被引 14
- An exploratory study of CT radiomics using differential network feature selection for WHO/ISUP grading and progression-free survival prediction of clear cell renal cell carcinomaYin, Fu; Zhang, Haijie; Qi, Anqi; Zhu, Zexuan; Yang, Liyang; Wen, Ge*; Xie, Weixin*Frontiers in Oncology, 2022, 12: 979613.
- Multiphase Contrast-Enhanced CT-Based Machine Learning Models to Predict the Fuhrman Nuclear Grade of Clear Cell Renal Cell CarcinomaLai, Shengsheng; Sun, Lei; Wu, Jialiang; Wei, Ruili; Luo, Shiwei; Ding, Wenshuang; Liu, Xilong; Yang, Ruimeng*; Zhen, Xin*Cancer Management and Research, 2021, 13: 999-1008.被引 8
